A fourth shot’s protection against serious sickness did not fade after six weeks, but its defenses against infection did.

Israelis aged 60-plus could get a fourth Pfizer BioNTech vaccine from early 2022.

In new research, published today in NEJM, of nearly 1.2 million older Israelis, those given a fourth dose had 3.5 times lower rate of severe COVID-19 disease in the fourth week after treatment than those given a triple dose.

A fourth vaccine also held up against becoming infected – in the same timeframe, confirmed infection was twice as low compared to three doses.

The protection against serious illness from a fourth shot didn’t wane within six weeks, however, its defences against infection declined during this timespan.

Updating more soon…

Source: 10.1056/NEJMoa2201570

Image Credit: Getty

You were reading: Yearly Two vaccine shots are enough to prevent severe COVID – new study suggests